Department of Emergency Medicine, Yale School of Medicine, 464 Congress Avenue, New Haven, CT 06519-1362, USA.
Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, 1340 Jefferson Park Avenue, Charlottesville, VA 22908, USA.
J Mol Biol. 2019 Jan 4;431(1):88-101. doi: 10.1016/j.jmb.2018.05.044. Epub 2018 Jun 7.
With the emergence of CRISPR technology, targeted editing of a wide variety of genomes is no longer an abstract hypothetical, but occurs regularly. As application areas of CRISPR are exceeding beyond research and biomedical therapies, new and existing ethical concerns abound throughout the global community about the appropriate scope of the systems' use. Here we review fundamental ethical issues including the following: 1) the extent to which CRISPR use should be permitted; 2) access to CRISPR applications; 3) whether a regulatory framework(s) for clinical research involving human subjects might accommodate all types of human genome editing, including editing of the germline; and 4) whether international regulations governing inappropriate CRISPR utilization should be crafted and publicized. We conclude that moral decision making should evolve as the science of genomic engineering advances and hold that it would be reasonable for national and supranational legislatures to consider evidence-based regulation of certain CRISPR applications for the betterment of human health and progress.
随着 CRISPR 技术的出现,对各种基因组进行靶向编辑不再是一个抽象的假设,而是经常发生的事情。随着 CRISPR 的应用领域超出了研究和生物医学治疗,全球范围内对该系统使用的适当范围存在着新的和现有的伦理问题。在这里,我们回顾了一些基本的伦理问题,包括:1)CRISPR 的使用应该在多大程度上被允许;2)CRISPR 应用的获取;3)是否有针对涉及人类受试者的临床研究的监管框架能够适应所有类型的人类基因组编辑,包括对生殖系的编辑;4)是否应该制定和公布规范不当 CRISPR 利用的国际法规。我们的结论是,随着基因组工程学的进步,道德决策应该发展,并且国家和超国家立法机构考虑对某些 CRISPR 应用进行基于证据的监管,以促进人类健康和进步,这是合理的。